Handelsavisen
prelaunch
Companies ›Healthcare ›FBLG
FB
FBLG — Nasdaq Pharmaceuticals

FibroBiologics, Inc.

$0,78
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,9M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-192,3 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,86
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

FibroBiologics, Inc. is classified under Healthcare / Pharmaceuticals and appears not currently profitable on the latest normalized snapshot.

Business. FibroBiologics, Inc. (Nasdaq: FBLG) is a healthcare company operating within the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification78 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
Generated · rules-based
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability→
-192,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning FBLG.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to FBLG. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    FibroBiologics, Inc. (FBLG) has recorded its first institutional holder activity in this analysis cycle, marking a notable shift in ownership structure. Three distinct investors have added positions in the company, signaling emerging interest from the institutional community. This development is particularly significant given that the company previously had no tracked holder changes, establishing a new baseline for monitoring capital flows into the biotech firm. The most substantial addition came from an investor who held 918,964 shares as of June 30, 2024, representing a portfolio value of approximately $4.59 million. This position accounted for a weight of roughly 0.0001% in the investor's portfolio, indicating a focused but relatively small allocation. Another notable entry occurred by year-end 2025, with an investor acquiring 1,216,341 shares valued at $0.27 million, reflecting a significant increase in share count compared to earlier periods. A third investor added a smaller position of 34,540 shares as of December 31, 2024, valued at $0.07 million. While this position is modest in absolute terms, its inclusion among the top holders underscores a broadening base of institutional participation. These additions collectively contribute to the company's current roster of six top holders, providing a clearer picture of its shareholder composition. Despite this activity in ownership, FibroBiologics remains outside major market indices and lacks coverage from financial analysts. The company also reports zero officers in the current dataset, which may reflect data limitations rather than operational reality. As the first analysis for this ticker, these holder changes provide the initial reference point for future delta computations, highlighting the importance of tracking institutional engagement in early-stage biotech firms.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    FibroBiologics, Inc. (Nasdaq: FBLG) is a healthcare company operating within the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification78 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    FibroBiologics, Inc. (FBLG) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on the latest snapshot: total assets 5,938,000 USD, total equity 2,600,000, short-term debt 0, long-term debt 0. Net cash position is approximately 1,482,000 USD. Self-calculated market cap is 3,248,493 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 0, gross profit 0, operating income -5,068,000, net income -5,000,000. Return on equity ~-192.3%. Return on assets ~-84.2%. Operating-cash-flow to net-income ratio is 0.87. Risk profile from automated assessment: liquidity risk high, dilution risk medium. Flags: Filings reference going-concern or substantial-doubt language.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] 8-K: 8-K (sec_8k_material) on FBLG — filing_type=8-K; max_severity=high; ignored_items=['7.01', '9.01']; material_items=['5.02']; all_items_found=['5.02', '7.01', '9.01']; severity_per_code={'5.02': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001193125-26-299290). Additional context: 8-K: filing_type=8-K; max_severity=high; ignored_items=['7.01', '9.01']; material_items=['5.02']; all_items_found=['5.02', '7.01', '9.01']; severity_per_code={'5.02': 'high'}; contributing_watchers=sec_8k_material.

    FibroBiologics, Inc. (FBLG) has recorded its first institutional holder activity in this analysis cycle, marking a notable shift in ownership structure. Three distinct investors have added positions in the company, signaling emerging interest from the institutional community. This development is particularly significant given that the company previously had no tracked holder changes, establishing a new baseline for monitoring capital flows into the biotech firm. The most substantial addition came from an investor who held 918,964 shares as of June 30, 2024, representing a portfolio value of approximately $4.59 million. This position accounted for a weight of roughly 0.0001% in the investor's portfolio, indicating a focused but relatively small allocation. Another notable entry occurred by year-end 2025, with an investor acquiring 1,216,341 shares valued at $0.27 million, reflecting a significant increase in share count compared to earlier periods. A third investor added a smaller position of 34,540 shares as of December 31, 2024, valued at $0.07 million. While this position is modest in absolute terms, its inclusion among the top holders underscores a broadening base of institutional participation. These additions collectively contribute to the company's current roster of six top holders, providing a clearer picture of its shareholder composition. Despite this activity in ownership, FibroBiologics remains outside major market indices and lacks coverage from financial analysts. The company also reports zero officers in the current dataset, which may reflect data limitations rather than operational reality. As the first analysis for this ticker, these holder changes provide the initial reference point for future delta computations, highlighting the importance of tracking institutional engagement in early-stage biotech firms.

    Key takeaways
    • Return on equity is about -192.3%.
    • Debt to equity is about 0.0x.
    • [TRIGGER] 8-K: 8-K (sec_8k_material) on FBLG — filing_type=8-K; max_severity=high; ignored_items=['7.01', '9.01']; material_items=['5.02']; all_items_found=['5.02', '7.01', '9.01']; severity_per_code={'5.02': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001193125-26-299290)
    • 10-Q 0001958777 December 31 false Q1 0.05 0.05 0.05 http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 3 P0Y 0001958777 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001958777 us-gaap:CommonStockMember fblg:VotingCommonStockMember 2025-01-01 2025-03-31 0001958777 us-gaap:ResearchAndDevelopmentExpenseMember 2026-01-01 2026-03-31 0001958777 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001958777 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001958777 us-gaap:CommonStockMember us-gaap:InvestorMember 2026-03-12 0001958777 2026-03-31 0001958777 fblg:StandbyEquityPurchaseAgreementMember 2025-01-01 2025-03-31 0001958777 2025-06-16 0001958777 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001958777 fblg:OfficeSpaceMember fblg:LeaseAgreementMember 2022-10-31 0001958777 2026-01-01 2026-03-31 0001958777 us-gaap:SubsequentEventMember 2026-05-01 2026-05-01 0001958777 fblg:StandbyEquityPurchaseAgreementMember 2024-12-20 2024-12-20 0001958777 us-gaap:CommonStockMember fblg:VotingCommonStockMember 2025-12-31 0001958777 us-gaap:GeneralAndAdministrativeExpenseMember 2026-01-01 2026-03-31 0001958777 stpr:TX fblg:LeaseAgreementMember 2025-03-31 2025-03-31 0001958777 us-gaap:RetainedEarningsMember 2026-03-31 0001958777 fblg:OfficeSpaceMember fblg:LeaseAgreementMember 2022-10-31 2022-10-31 0001958777 us-gaap:CommonStockMember fblg:VotingCommonStockMember 2024-12-31 0001958777 fblg:GoldenKnightIncorporatedLPMember 2026-03-31 0001958777 fblg:StandbyEquityPurchaseAgreementMember 2025-12-31 0001958777 us-gaap:EmployeeStockOptionMember 2026-03-31 0001958777 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001958777 stpr:TX fblg:LeaseAgreementMember 2025-03-31 0001958777 us-gaap:CommonStockMember us-gaap:InvestorMember 2026-03-24 2026-03-24 0001958777 fblg:AprilTwoTwoThousandAndTwentySixRegisteredOfferingMember 2026-04-02 2026-04-02 0001958777 us-gaap:FairValueInputsLevel3Member fblg:SEPAPutOptionLiabilityMember 2024-12-31 0001958777 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001958777 us-gaap:CommonStockMember us-gaap:InvestorMember 2026-03-24 0001958777 fblg:LaboratoryEquipmentMember 2026-03-31 0001958777 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001958777 us-gaap:EmployeeStockOptionMember 2025-12-31 0001958777 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001958777 us-gaap:CommonStockMember fblg:AprilTwoTwoThousandAndTwentySixRegisteredOfferingMember 2026-04-02 0001958777 fblg:TemporaryLabAndOfficeSpaceMember fblg:LeaseAgreementMember 2023-06-30 0001958777 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001958777 fblg:ComputerEquipmentSoftwareAndOtherMember 2025-12-31 0001958777 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001958777 fblg:GoldenKnightIncorporatedLPMember 2026-01-01 2026-03-31 0001958777 us-gaap:FairValueInputsLevel3Member fblg:ShortTermConvertibleNotesPayableMember 2024-12-31 0001958777 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001958777 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001958777 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001958777 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001958777 fblg:LeaseAgreementSecondAmendmentMember fblg:TemporaryLabAndOfficeSpaceMember 2024-07-01 2024-07-31 0001958777 fblg:AprilTwoTwoThousandAndTwentySixRegisteredOfferingMember fblg:PrefundedWarrantMember srt:MaximumMember 2026-04-02 0001958777 us-gaap:MeasurementInputMaturityMember fblg:StandbyEquityPurchaseAgreementMember 2025-03-31 0001958777 us-gaap:FairValueInputsLevel3Member fblg:SEPAPutOptionLiabilityMember 2025-12-31 0001958777 us-gaap:CommonStockMember fblg:VotingCommonStockMember 2025-03-31 0001958777 fblg:ShortTermConvertibleNotesPayableMember us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-03-31 0001958777 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001958777 fblg:StandbyEquityPurchaseAgreementMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001958777 srt:MaximumMember 2026-03-31 0001958777 fblg:TemporaryLabAndOfficeSpaceMember fblg:LeaseAgreementSecondAmendmentMember 2024-07-31 0001958777 us-gaap:WarrantMember fblg:AprilTwoTwoThousandAndTwentySixRegisteredOfferingMember 2026-04-02 0001958777 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001958777 srt:MinimumMember 2026-03-31 0001958777 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001958777 2024-12-31 0001958777 us-gaap:RetainedEarningsMember 2025-03-31 0001958777 us-gaap:MeasurementInputMaturityMember 2024-03-31 0001958777 us-gaap:FairValueInputsLevel3Member fblg:SEPAPutOptionLiabilityMember 2025-01-01 2025-03-31 0001958777 us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001958777 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001958777 2025-01-01 2025-12-31 0001958777 fblg:Pre-FundedWarrantsMember srt:MaximumMember 2026-03-31 0001958777 us-gaap:CommonStockMember us-gaap:InvestorMember 2026-03-18 2026-03-18 0001958777 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001958777 us-gaap:FairValueInputsLevel3Member fblg:SEPAPutOptionLiabilityMember 2025-03-31 0001958777 fblg:StandbyEquityPurchaseAgreementMember us-gaap:CommonStockMember 2024-12-20 2024-12-20 0001958777 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-31 0001958777 fblg:VotingCommonStockMember 2026-03-31 0001958777 us-gaap:FairValueInputsLevel3Member fblg:ShortTermConvertibleNotesPayableMember 2025-03-31 0001958777 2025-03-31 0001958777 us-gaap:RetainedEarningsMember 2025-12-31 0001958777 us-gaap:CommonStockMember fblg:VotingCommonStockMember 2026-01-01 2026-03-31 0001958777 us-gaap:RetainedEarningsMember 2024-12-31 0001958777 fblg:ComputerEquipmentSoftwareAndOtherMember 2026-03-31 0001958777 us-gaap:FairValueInputsLevel3Member fblg:SEPAPutOptionLiabilityMember 2026-01-01 2026-03-31 0001958777 us-gaap:WarrantMember fblg:AprilTwoTwoThousandAndTwentySixRegisteredOfferingMember srt:MaximumMember 2026-04-02 0001958777 fblg:StandbyEquityPurchaseAgreementMember 2025-03-31 0001958777 fblg:LeaseAgreementSecondAmendmentMember fblg:TemporaryLabAndOfficeSpaceMember 2024-03-01 2024-03-31 0001958777 us-gaap:SeriesCPreferredStockMember 2026-03-31 0001958777 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2026-04-02 0001958777 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001958777 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001958777 2024-12-30 0001958777 fblg:LaboratoryEquipmentMember 2025-12-31 0001958777 2026-05-01 0001958777 us-gaap:MeasurementInputPriceVolatilityMember fblg:StandbyEquityPurchaseAgreementMember 2025-03-31 0001958777 fblg:VotingCommonStockMember 2025-12-31 0001958777 us-gaap:MeasurementInputPriceVolatilityMember 2024-03-31 0001958777 fblg:LaborataryEquipmentMember 2026-03-31 0001958777 us-gaap:CommonStockMember fblg:VotingCommonStockMember 2026-03-31 0001958777 us-gaap:MeasurementInputSharePriceMember 2025-03-31 0001958777 us-gaap:CommonStockMember us-gaap:InvestorMember 2026-03-12 2026-03-12 0001958777 us-gaap:CommonStockMember us-gaap:InvestorMember 2026-03-18 0001958777 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001958777 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001958777 fblg:LeaseAgreementAmendmentMember fblg:TemporaryLabAndOfficeSpaceMember 2023-09-01 2023-09-30 0001958777 fblg:TemporaryLabAndOfficeSpaceMember fblg:LeaseAgreementMember 2023-06-01 2023-06-30 0001958777 us-gaap:MeasurementInputMaturityMember 2025-03-31 0001958777 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001958777 fblg:AprilTwoTwoThousandAndTwentySixRegisteredOfferingMember fblg:PrefundedWarrantMember 2026-04-02 0001958777 us-gaap:FairValueInputsLevel3Member fblg:SEPAPutOptionLiabilityMember 2026-03-31 0001958777 2025-12-31 0001958777 2025-01-01 2025-03-31 0001958777 us-gaap:MeasurementInputSharePriceMember 2024-03-31 0001958777 fblg:StandbyEquityPurchaseAgreementMember 2026-01-01 2026-03-31 xbrli:pure utr:sqft xbrli:shares iso4217:USD xbrli:shares iso4217:USD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
    • Organization, Description of Business, and Liquidity Organization and Business FibroBiologics, Inc.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights
    Open report →

    Operating income -$5.1M.

    Revenue—
    Operating income-$5.1M
    Net income-$5.0M
    Free cash flow-$4.4M
    EPS—
    Operating cash flow-$4.4M
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income-$5.1M
    Net income-$5.0M
    Balance sheet
    Total assets$5.9M
    Total liabilities$3.3M
    Total equity$2.6M
    Cash & equivalents$1.5M
    Long-term debt—
    Cash flow
    Operating cash flow-$4.4M
    CapEx$0.00
    Free cash flow-$4.4M
    SBC$694.0k
    Highlights
    • ▍Operating income -$5.1M

    Valuation FY

    Market price
    $0,78
    Market cap
    $3.2M
    Enterprise valueⓘ
    $1.8M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    1.2x
    P / Tangible bookⓘ
    1.2x
    Tangible book
    $2.6M
    Net cashⓘ
    $1.5M
    Current ratioⓘ
    1.6
    Debt / equityⓘ
    —
    ROAⓘ
    -84.2%
    ROEⓘ
    -1.9%
    Cash conversionⓘ
    87.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    —

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-07-27

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskHigh
    Filing-based flags
    • Filings reference going-concern or substantial-doubt language.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    ROE-192,3 %Bottom quartile
    D/E0,00Above P75
    Cash Conv0,87Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 400 443 sh8 grants8 insiders
    • Hoffman Robert E.Director · Stock Option (Right to Buy) → Common StockAcquired 30 803 @ $0,75grant · 2026-06-23
    • Cilento Richard C. Jr.Director · Stock Option (Right to Buy) → Common StockAcquired 30 803 @ $0,75grant · 2026-06-23
    • Link MatthewDirector · Stock Option (Right to Buy) → Common StockAcquired 30 803 @ $0,75grant · 2026-06-23
    • Niklas Victoria Ninon OliviaDirector · Stock Option (Right to Buy) → Common StockAcquired 30 803 @ $0,75grant · 2026-06-23
    • GARCIA RUBEN AGeneral Counsel · Stock Option (Right to Buy) → Common StockAcquired 61 607 @ $1,38grant · 2026-05-04
    • O'HEERON PETEDirector, CHIEF EXECUTIVE OFFICER · Stock Option (Right to Buy) → Common StockAcquired 92 410 @ $1,38grant · 2026-05-04
    • Khoja HamidChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 61 607 @ $1,38grant · 2026-05-04
    • Davis JasonChief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 61 607 @ $1,38grant · 2026-05-04

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    • Return On Assets
      net_income / total_assets
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Enterprise Value
      market_cap - net_cash
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • FibroBiologics, Inc. company facts · 2026-07-10
    • FibroBiologics, Inc. 10-Q 2026-04-30 · 2026-07-10
    • FibroBiologics, Inc. 10-K 2026-02-24 · 2026-07-10
    • FibroBiologics, Inc. 10-Q 2025-10-31 · 2026-07-10
    • FibroBiologics, Inc. 10-Q 2025-07-31 · 2026-07-10
    • 8-K (sec_8k_material) on FBLG · 2026-07-10

    Ownership & reference

    Top holders

    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$5M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying7 buys · 0 sellsnet $121K4 insiders · last 365d
    • Khoja HamidChief Scientific Officer · Common StockBought 30 000 @ $0,38$11K · 2026-03-04
    • O'HEERON PETEDirector, CHIEF EXECUTIVE OFFICER · Common StockBought 15 872 @ $0,38$6K · 2026-03-04
    • O'HEERON PETEDirector, CHIEF EXECUTIVE OFFICER · Common StockBought 18 200 @ $0,41$7K · 2026-03-03
    • Davis JasonChief Financial Officer · Common StockBought 70 000 @ $0,41$29K · 2026-03-02
    • O'HEERON PETEDirector, CHIEF EXECUTIVE OFFICER · Common StockBought 17 428 @ $0,35$6K · 2026-03-02
    • GARCIA RUBEN AGeneral Counsel · Common StockBought 40 000 @ $0,33$13K · 2026-02-27
    • GARCIA RUBEN AGeneral Counsel · Common StockBought 140 000 @ $0,34$48K · 2025-12-11

    Short positioning

    70.8Kshares short-47.8% vs prior
    1.19days to cover
    54.6%short of daily vol
    5.1Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    FBLGCanonical
    Nasdaq · USD

    Intel & risk

    PredictorM&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskMedium
    Liquidity riskHigh
    Filings reference going-concern or substantial-doubt language.
    Source documents mention dilution or offering risk.

    Evidence & claims

    From filings & derived data
    • Total operating expenses (annual): USD 16.65MUnknown
    • Shareholders' equity (annual): USD 6.16MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -0Unknown
    • Net income (annual): USD -18.65MUnknown
    • R&D expense (annual): USD 7.41MUnknown
    • Current liabilities (annual): USD 1.76MUnknown
    • Operating income (annual): USD -16.65MUnknown
    • Current assets (annual): USD 6.35MUnknown
    • Total liabilities (annual): USD 3.46MUnknown
    • Cash & equivalents (annual): USD 4.89MUnknown
    • Capex (annual): USD 262KUnknown
    • Total assets (annual): USD 9.62MUnknown
    • Operating cash flow (annual): USD -16.39MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -0Unknown
    • Operating cash flow (annual): USD -11.9MUnknown
    • Total liabilities (annual): USD 13.71MUnknown
    • Total operating expenses (annual): USD 13.74MUnknown
    • Operating income (annual): USD -13.74MUnknown
    • Capex (annual): USD 184KUnknown
    • Shareholders' equity (annual): USD 2.73MUnknown
    • R&D expense (annual): USD 4.5MUnknown
    • Cash & equivalents (annual): USD 13.98MUnknown
    • Total assets (annual): USD 16.45MUnknown
    • Current liabilities (annual): USD 12.73MUnknown
    Showing 24 of 26 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-10 04:37 UTCFILINGMaterial 8-K
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDER3 institutional position changes flagged
    2026-06-23 00:00 UTCINSIDER4 insider transactions — 2026-06 4 derivative
    2026-06-23INSIDERHoffman Robert E. acquired 30.8k sh Stock Option (Right to Buy) — Director
    2026-06-23INSIDERLink Matthew acquired 30.8k sh Stock Option (Right to Buy) — Director
    2026-06-23INSIDERNiklas Victoria Ninon Olivia acquired 30.8k sh Stock Option (Right to Buy) — Director
    2026-06-23INSIDERCilento Richard C. Jr. acquired 30.8k sh Stock Option (Right to Buy) — Director
    2026-05-06FILING8-K filing →
    2026-05-06FILING424B5 filing →
    2026-05-05FILING8-K filing →
    2026-05-05FILINGDEF 14A filing →
    2026-05-04 00:00 UTCINSIDER4 insider transactions — 2026-05 4 derivative
    2026-05-04INSIDERO'HEERON PETE acquired 92.4k sh Stock Option (Right to Buy) — Director, CHIEF EXECUTIVE OFFICER
    2026-05-04INSIDERKhoja Hamid acquired 61.6k sh Stock Option (Right to Buy) — Chief Scientific Officer
    2026-05-04INSIDERDavis Jason acquired 61.6k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-05-04INSIDERGARCIA RUBEN A acquired 61.6k sh Stock Option (Right to Buy) — General Counsel
    2026-05-01FILING424B5 filing →
    2026-05-01FILING8-K filing →
    2026-04-30FILING10-Q filing →
    2026-04-20FILING8-K filing →
    2026-04-17FILING8-K filing →
    2026-04-09FILING8-K filing →
    2026-04-03FILING8-K filing →
    2026-04-02FILING8-K filing →
    2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -5.0M
    2026-03-04 00:00 UTCINSIDER5 insider transactions — 2026-03
    2026-03-04INSIDERKhoja Hamid bought 30.0k sh — Chief Scientific Officer ~$11k
    2026-03-04INSIDERO'HEERON PETE bought 15.9k sh — Director, CHIEF EXECUTIVE OFFICER ~$6k
    2026-03-03INSIDERO'HEERON PETE bought 18.2k sh — Director, CHIEF EXECUTIVE OFFICER ~$7k
    2026-03-02INSIDERDavis Jason bought 70.0k sh — Chief Financial Officer ~$29k
    2026-03-02INSIDERO'HEERON PETE bought 17.4k sh — Director, CHIEF EXECUTIVE OFFICER ~$6k
    2026-02-27 00:00 UTCINSIDER1 insider transaction — 2026-02
    2026-02-27INSIDERGARCIA RUBEN A bought 40.0k sh — General Counsel ~$13k
    2025-12-31EARNINGSQuarterly results — Q3 2025
    2025-12-31EARNINGSAnnual results — FY 2025 Net USD -18.6M
    Showing the 40 most recent of 49 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage